文献速递传染病防控与疫情报告免疫规划

海地灭活双价全菌体口服霍乱疫苗单剂与两剂长期效果:扩展病例对照研究

Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study.
PubMed 文献 · Lancet Glob Health · 2018-01-01

在海地疫情及新地方性流行背景下,开展病例对照研究评估灭活双价全菌体口服霍乱疫苗单剂与两剂接种后长达4年的保护效果。纳入178例病例和706例对照,调整分析显示两剂4年累计效果为76%(95%CI 59-86),单剂效果随时间下降,12个月末为79%(95%CI 43-93),第二年内降至零。结论认为单剂提供短期保护,两剂为长期保护所需,支持将本疫苗纳入综合霍乱控制计划。

要点

  • 两剂口服霍乱疫苗4年累计效果为76%(95%CI 59-86),随访期间未见下降。
  • 单剂效果呈对数线性下降,12个月末为79%(95%CI 43-93),第二年内降至零。
  • 单剂提供短期保护,两剂为长期保护所需,支持将本疫苗纳入综合霍乱控制计划。

核心结论

  • 在海地疫情和新地方性流行背景下,单剂灭活双价全菌体口服霍乱疫苗提供短期保护,两剂为长期保护所需,保护可持续至接种后4年。

研究设计与样本

  • 病例对照研究,2012年10月至2016年11月在海地阿蒂博尼特省或中部省疫苗覆盖区开展,纳入178例病例和706例对照。

主要发现

  • 两剂平均4年累计效果为76%(95%CI 59-86),随访期间未见效果下降证据。
  • 单剂效果随时间呈对数线性下降,12个月末预测效果为79%(95%CI 43-93),第二年内降至零。

关键数值与推荐

  • 主要结局为接种后2至48个月单剂和两剂相对于零剂的疫苗效果,通过自我报告测量。
  • 两剂4年累计效果为76%(95%CI 59-86);单剂12个月末效果为79%(95%CI 43-93),第二年内降至零。

临床怎么用

  • 作者认为结果支持将灭活双价全菌体口服霍乱疫苗作为综合霍乱控制计划的一部分使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No study of long-term protection following killed oral cholera vaccination has been done outside of the historically cholera-endemic areas of south Asia, or has examined protection after a single-dose vaccination regimen. To address this, we examined the duration of protection of the standard two-dose regimen and an incomplete regimen of one dose up to 4 years after vaccination in Haiti. METHODS: In the setting of two-dose vaccination campaigns with a killed, bivalent, whole-cell oral cholera vaccination, we did a case-control study from October, 2012 through November, 2016. Eligible participants were required to be resident in the vaccine catchment area (Artibonite Department or Central Department) where they were recruited at the start of the study; and be eligible for the vaccination campaign (ie, aged ≥12 months, not pregnant, and living in the region at the time of the vaccine campaign). Patients with cholera had a positive stool culture and were recruited from cholera treatment centres. Community controls were matched to people with cholera by age group, time, and neighbourhood. We did adjusted matched regression analyses to calculate vaccine effectiveness and examine heterogeneity in effectiveness over time. The primary outcome was the effectiveness of one and two oral cholera doses as compared with zero doses from 2 months to 48 months after vaccination, measured by self reporting. FINDINGS: Among 178 people assigned to the case group and 706 people assigned to the control group, we found no evidence that two-dose effectiveness decreased during follow-up. In adjusted analyses, the average cumulative 4 year effectiveness for two doses was 76% (95% CI 59-86). In contrast, single-dose effectiveness decreased over time in a log-linear fashion, with a predicted vaccine effectiveness of 79% at the end of 12 months (95% CI 43-93), which declined to zero before the end of the second year. INTERPRETATION: In a setting of epidemic and newly endemic cholera in Haiti, single-dose vaccination with killed, bivalent, whole-cell oral cholera vaccination provided short-term protection; however, vaccination with two doses was required for long-term protection, which lasted up to 4 years after vaccination. These results add to the evidence in support of the use of killed, bivalent, whole-cell oral cholera vaccination as part of comprehensive cholera control plans. FUNDING: US National Institute of Allergy and Infectious Diseases of the National Institutes of Health and the Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Franke MF, Ternier R, Jerome JG, et al. Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study. Lancet Glob Health. 2018. PMID: 30103980. doi:10.1016/S2214-109X(18)30284-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。